Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation

Kahn Swick & Foti is investigating Rallybio Corporation’s proposed merger with Avenzo Therapeutics, including whether the merger and the process leading to it are adequate. Rallybio’s pre-transaction equityholders are expected to own approximately 2.8% of the combined company upon completion. The article provides no findings or outcome from the investigation.

Analysis

The 2.8% residual ownership is a potential value-transfer signal, not evidence by itself that the deal is unfair: the key question is what Rallybio contributes versus the assets, cash, and financing Avenzo brings. The shareholder-investigation headline has low information content unless it develops into a filed complaint, a material proxy disclosure, or a transaction delay. Its near-term effect is more likely added event uncertainty than a change in the combined company’s fundamentals.

Over the next 1–3 months, focus on the merger agreement and proxy: consideration and exchange mechanics, relative asset and cash contributions, any contingent value rights, treatment of existing liabilities, financing commitments, and the expected post-close capitalization. These determine whether the small legacy stake reflects weak bargaining power or substantial value from Avenzo’s contribution. Over 6–18 months, execution and access to capital matter more than the ownership split; a thin legacy stake could still benefit if the combined company funds development and creates value, but it leaves Rallybio holders with limited participation in that upside.

The contrarian read is that routine law-firm investigations can look like a deal-breaker without changing closing odds. Conversely, assuming the transaction is safe because the headline is routine misses the possibility that disclosure or approval issues surface in the proxy. No valuation or spread conclusion is supportable without transaction terms and current trading data.

Key Decisions for Investors

• Do not trade the investigation headline alone. Before taking RLYB event risk, verify the merger consideration, expected closing timeline, financing conditions, termination rights, and the unaffected share price.
• Treat a widening deal discount as actionable only if it exceeds what the stated consideration and ordinary closing risks imply; reassess if a complaint is filed, proxy disclosures change, or a court or regulator threatens timing.
• Watch the proxy for the post-merger fully diluted share count, cash and liabilities contributed by each party, and any contingent-value provisions. These are the critical tests of whether 2.8% is economically justified.
• Falsify the low-information-risk view if the company revises deal terms, discloses material process or valuation concerns, or approval/closing timing slips; absent those developments, there is no clear standalone long/short signal.